N/A
N=349
Impact of Heart Failure Center Program on Cardiac Outcomes in Patients With Heart Failure
Death · Congestive Heart Failure
Bottom Line
View on ClinicalTrials.gov: NCT01416285 ↗Enrolled (actual)
349
Serious AEs
17.3%
Results posted
Mar 2024
Primary outcome: Primary: All-cause Death, Heart Failure-related Re-hospitalizations, and a Composite Outcome of Both Death and Heart Failure-related Re-hospitalizations — 36; 15; 41; 18 Participants — p=0.004
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- —
- Age
- Adult, Older Adult · 20+ yrs
- Sex
- All
- Sponsor
- Chang Gung Memorial Hospital
- Primary completion
- May 2012
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY All-cause Death, Heart Failure-related Re-hospitalizations, and a Composite Outcome of Both Death and Heart Failure-related Re-hospitalizations |
36; 15; 41; 18; 63; 28 | 0.004 sig |
Summary
Congestive heart failure (CHF) is a major public health problem worldwide. CHF carries a devastating prognosis, which resembles that of some types of malignant cancer. Despite substantial improvements in the management of the disease, the prognosis remains poor especially in advanced stages of the disease. For these patients, self-management plan includes monitoring of symptoms such as fatigue and shortness of breath, daily weighing, and knowing what to do if signs of deterioration appear, and when to report the changes to health. The investigators hypothesize that patients in the heart failure management programs that promote self-management by means of intensive education, edema index-assistance, and telephone follow-up can improve their functional status and quality of life, as well as the biomarkers of CHF, left ventricular systolic function, proteinuria and nutritional status.
Eligibility Criteria
Inclusion Criteria
- patients hospitalized due to acute cardiogenic pulmonary edema documented on chest x-ray and
- left ventricular ejection fraction (LVEF) 20 and 3 months and/or unable to stand alone;
- having serum creatinine of > 5 mg/dl or nephritic syndrome;
- having active cellulites, severe varicose veins, lymphedema or deep vein thrombosis over lower extremity;
- undergoing dialysis within 2 weeks;
- having severe coronary artery disease without complete revascularization therapy; and
- being pregnant.
Data sourced from ClinicalTrials.gov (NCT01416285). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.